Emami Ltd
Emami is engaged in manufacturing & marketing of personal care & healthcare products with an enviable portfolio of household brand names such as BoroPlus, Navratna, Fair and Handsome, Zandu Balm, Kesh King, Zandu Pancharishta, Mentho Plus Balm and others.(Source : 201903 Annual Report Page No: 193)
- Market Cap ₹ 24,346 Cr.
- Current Price ₹ 558
- High / Low ₹ 860 / 417
- Stock P/E 31.5
- Book Value ₹ 60.2
- Dividend Yield 1.42 %
- ROCE 31.7 %
- ROE 30.0 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.8%
- Company has been maintaining a healthy dividend payout of 48.5%
Cons
- Stock is trading at 9.29 times its book value
- The company has delivered a poor sales growth of 5.84% over past five years.
- Tax rate seems low
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Personal Care - Indian
Part of BSE Quality Index Nifty Midcap150 Quality 50 Nifty 500 Nifty LargeMidcap 250 BSE Fast Moving Consumer Goods
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,595 | 1,700 | 2,076 | 2,358 | 2,488 | 2,531 | 2,695 | 2,655 | 2,881 | 3,192 | 3,406 | 3,578 | 3,684 | |
1,252 | 1,255 | 1,536 | 1,670 | 1,729 | 1,812 | 1,970 | 1,970 | 2,000 | 2,254 | 2,550 | 2,632 | 2,701 | |
Operating Profit | 343 | 445 | 541 | 688 | 759 | 719 | 725 | 685 | 880 | 938 | 855 | 946 | 984 |
OPM % | 22% | 26% | 26% | 29% | 31% | 28% | 27% | 26% | 31% | 29% | 25% | 26% | 27% |
54 | 53 | 91 | 44 | 31 | 19 | 25 | 46 | 69 | 90 | 69 | 41 | 54 | |
Interest | 7 | 5 | 5 | 54 | 58 | 34 | 21 | 21 | 13 | 5 | 7 | 10 | 10 |
Depreciation | 22 | 35 | 34 | 255 | 309 | 311 | 325 | 336 | 367 | 335 | 247 | 186 | 183 |
Profit before tax | 369 | 457 | 592 | 423 | 424 | 393 | 403 | 374 | 569 | 688 | 670 | 791 | 844 |
Tax % | 15% | 12% | 18% | 14% | 20% | 22% | 25% | 19% | 20% | -22% | 6% | 8% | |
315 | 402 | 485 | 363 | 340 | 306 | 303 | 302 | 455 | 837 | 627 | 724 | 769 | |
EPS in Rs | 6.93 | 8.87 | 10.70 | 8.00 | 7.50 | 6.77 | 6.68 | 6.67 | 10.23 | 19.02 | 14.50 | 16.58 | 17.70 |
Dividend Payout % | 38% | 39% | 33% | 44% | 47% | 52% | 60% | 60% | 78% | 42% | 55% | 48% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 6% |
3 Years: | 8% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 6% |
5 Years: | 19% |
3 Years: | 18% |
TTM: | 12% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | 10% |
3 Years: | 4% |
1 Year: | 6% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 28% |
3 Years: | 33% |
Last Year: | 30% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 23 | 23 | 23 | 23 | 23 | 45 | 45 | 44 | 44 | 44 | 44 | 44 |
Reserves | 762 | 909 | 1,208 | 1,589 | 1,732 | 1,991 | 2,031 | 1,778 | 1,718 | 2,032 | 2,259 | 2,403 | 2,585 |
115 | 38 | 36 | 671 | 473 | 326 | 110 | 210 | 101 | 282 | 91 | 94 | 74 | |
324 | 333 | 410 | 409 | 376 | 458 | 633 | 644 | 656 | 692 | 703 | 728 | 891 | |
Total Liabilities | 1,216 | 1,302 | 1,676 | 2,692 | 2,603 | 2,798 | 2,819 | 2,678 | 2,520 | 3,050 | 3,096 | 3,269 | 3,594 |
397 | 396 | 453 | 1,918 | 1,994 | 1,802 | 1,680 | 1,459 | 1,132 | 1,344 | 1,245 | 1,114 | 1,039 | |
CWIP | 47 | 12 | 29 | 67 | 22 | 30 | 36 | 8 | 6 | 3 | 6 | 8 | 9 |
Investments | 163 | 296 | 501 | 104 | 128 | 314 | 187 | 156 | 255 | 303 | 293 | 442 | 624 |
609 | 599 | 693 | 604 | 460 | 652 | 915 | 1,055 | 1,126 | 1,400 | 1,551 | 1,706 | 1,922 | |
Total Assets | 1,216 | 1,302 | 1,676 | 2,692 | 2,603 | 2,798 | 2,819 | 2,678 | 2,520 | 3,050 | 3,096 | 3,269 | 3,594 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
323 | 428 | 534 | 562 | 730 | 588 | 554 | 531 | 922 | 644 | 749 | 779 | |
-130 | -140 | -237 | -1,313 | -306 | -276 | -26 | -231 | -224 | -234 | -122 | -210 | |
-188 | -301 | -215 | 502 | -496 | -324 | -428 | -405 | -688 | -402 | -608 | -563 | |
Net Cash Flow | 5 | -13 | 82 | -249 | -72 | -12 | 100 | -106 | 9 | 8 | 19 | 6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 26 | 17 | 18 | 20 | 14 | 22 | 29 | 42 | 29 | 37 | 44 | 50 |
Inventory Days | 58 | 76 | 59 | 68 | 83 | 87 | 88 | 102 | 118 | 121 | 100 | 102 |
Days Payable | 52 | 77 | 90 | 112 | 85 | 109 | 115 | 135 | 138 | 138 | 124 | 143 |
Cash Conversion Cycle | 32 | 16 | -13 | -24 | 12 | 1 | 2 | 9 | 10 | 19 | 20 | 9 |
Working Capital Days | -7 | -6 | -13 | 3 | -37 | 15 | 9 | 36 | 9 | 31 | 37 | 38 |
ROCE % | 42% | 50% | 61% | 30% | 23% | 22% | 19% | 18% | 29% | 31% | 28% | 32% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12h - Conference call scheduled for Q3 FY25 results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jan - Certificate of compliance for dematerialization received.
- Corporate Action-Board To Consider 2Nd Interim Dividend 27 Dec
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Third Quarter Ending 31St December, 2024 And Consideration And Declaration Of 2Nd Interim Dividend For The FY 2024-25
27 Dec - Board meeting to approve Q3 results and interim dividend.
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 24 Dec
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jun 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016Transcript PPT
-
May 2016Transcript PPT
-
Jan 2016TranscriptPPT
Leadership in Niche segments:[1] Emami is one of the leading companies in the personal and healthcare segment with leadership in the niche Ayurvedic segment. The Company has a portfolio of 450+ products based on ayurvedic formulations.